Seminars in Oncology
Volume 30, Issue 2 , Pages 132-135, April 2003

The malignant clone in Waldenstrom's macroglobulinemia☆☆

Departments of Oncology and Medicine, University of Alberta, Cross Cancer Institute, Edmonton, Canada; and the Dana Farber Cancer Institute, Boston, MA.

Abstract 

The unique IgM VDJ sequence that characterizes the malignant clone in Waldenstrom's macroglobulinemia (WM), termed clonotypic, was identified for 12 WM patients. The majority of WM patients (92%) had a clonotypic IgM from the VH3 family, with predominantly long CDR3 regions, characteristic of those found in antigen-stimulated populations. Clonotypic IgM transcripts were detected in both blood and bone marrow (BM), clearly identifying a blood-borne compartment of WM. Abnormal numbers of CD20+ B cells were usually detectable and expressed surface IgM. In most cases these cells also expressed surface IgD. Most WM patients lacked detectable CD138+ plasma cells in either blood or BM. Longitudinal analysis suggests that phenotypic identification of B cells in blood of WM patients is insufficient for monitoring disease. Although serum IgM had decreased and clonotypic transcripts were very weak for one patient, the number of CD20+ B cells increased dramatically. The lack of clonotypic transcripts suggests that the majority of these circulating B cells were polyclonal and were not part of the WM clone, indicating that monitoring of clonotypic IgM provides the most accurate identifier of WM cells. Semin Oncol 30:132-135. © 2003 Elsevier Inc. All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a Smokler Award from the Research Fund for Waldenström's.

☆☆ Address reprint requests to Linda M. Pilarski, PhD, Department of Oncology, University of Alberta and Cross Cancer Institute, 11560 University Ave, Edmonton, Alberta, T6G 1Z2, Canada.

 0093-7754/03/3002-0026$30.00/0

PII: S0093-7754(03)70063-3

doi:10.1053/sonc.2003.50061

Seminars in Oncology
Volume 30, Issue 2 , Pages 132-135, April 2003